Skip to main content


(Reuters) - Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.
Glaucoma affects about 2.7 million people in the United States and is the second leading cause of blindness in the world.
Rhopressa helps lower the pressure due to a build up of fluid in the eye by targeting the trabecular meshwork, the main drain through which fluid flows out of the eye.

For more details: New breakthrough in ophthalmology

Comments

  1. Macular degeneration is the leading cause of severe, irreversible vision loss. It occurs when the small central portion of the retina, known as the macula, deteriorates. Most common symptoms of this disease is increasing age. Macular degeneration treatment

    ReplyDelete

Post a Comment

Popular posts from this blog

NEI Statistics
Retina and Retinal Disorders The retina is a layer of tissue present in the interior of your eye.   Retina    disorders   are mainly due to lack of light-delicate cells and other nerve cells which transform the impulse into visual information. Retina sends this visual data to the cerebrum through your optic nerve and process the information into an image and empowering you to see. Different age group generations, races and ethnicities are effected from   Retinal degenerative disorders , for instance,   Age-related macular degeneration   and   myopic macular degeneration . Click here to submit your abstract for the Retina session: